Your browser doesn't support javascript.
loading
Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.
Davis, Owen A; Cheung, Kwai-Ming J; Brennan, Alfie; Lloyd, Matthew G; Rodrigues, Matthew J; Pierrat, Olivier A; Collie, Gavin W; Le Bihan, Yann-Vaï; Huckvale, Rosemary; Harnden, Alice C; Varela, Ana; Bright, Michael D; Eve, Paul; Hayes, Angela; Henley, Alan T; Carter, Michael D; McAndrew, P Craig; Talbot, Rachel; Burke, Rosemary; van Montfort, Rob L M; Raynaud, Florence I; Rossanese, Olivia W; Meniconi, Mirco; Bellenie, Benjamin R; Hoelder, Swen.
Afiliação
  • Davis OA; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Cheung KJ; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Brennan A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Lloyd MG; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Rodrigues MJ; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Pierrat OA; Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Collie GW; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Le Bihan YV; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Huckvale R; Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Harnden AC; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Varela A; Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Bright MD; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Eve P; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Hayes A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Henley AT; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Carter MD; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • McAndrew PC; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Talbot R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Burke R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • van Montfort RLM; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Rossanese OW; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Meniconi M; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Bellenie BR; Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K..
  • Hoelder S; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K..
J Med Chem ; 65(12): 8169-8190, 2022 06 23.
Article em En | MEDLINE | ID: mdl-35657291

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Domínio BTB-POZ Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Domínio BTB-POZ Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido